Carlos M. de Castro

发表

Estimation of economic costs associated with transfusion dependence in adults with MDS*

J. Frytak, H. Henk, Carlos M. de Castro, 2009, Current medical research and opinion.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

C. Bloomfield, M. Millenson, H. Deeg, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

M. Vitek, Joseph O. Moore, J. Gockerman, 2011, Blood.

Myelodysplastic syndromes clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

F. Ali-Osman, A. Advani, L. Rybicki, 2010, Clinical lymphoma, myeloma & leukemia.

Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study.

A. Abernethy, G. Samsa, J. Troy, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant

T. Leblanc, D. Rizzieri, A. Sung, 2020, Blood Cancer Journal.

A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy

J. Lancet, D. Rizzieri, A. List, 2015, American journal of hematology.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

R. Neuwirth, K. Sullivan, L. Sutton, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

H. Deeg, R. Bejar, P. Greenberg, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Decitabine improves patient outcomes in myelodysplastic syndromes

John M Bennett, J. Issa, Lanlan Shen, 2006, Cancer.

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.

J. Panse, J. Szer, A. Risitano, 2021, The New England journal of medicine.

Hairy cell leukemia: an elusive but treatable disease.

Carlos M. de Castro, Sam O. Wanko, Carlos de Castro, 2006, The oncologist.

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

J. Maciejewski, E. Roman, R. Brodsky, 2020, American journal of hematology.

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

N. Young, J. Maciejewski, A. Risitano, 2008, Blood.

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

J. Maciejewski, J. Szer, A. Risitano, 2013, British journal of haematology.

Myelodysplastic syndromes, version 2.2015.

C. Bloomfield, H. Deeg, R. Bejar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Multiple myeloma. Clinical practice guidelines in oncology.

J. Vose, S. Singhal, C. Huff, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.

J. Panse, J. Szer, A. Risitano, 2022, The Lancet. Haematology.

3113 – FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

J. Panse, J. Szer, A. Risitano, 2021, Experimental Hematology.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

H. Goldschmidt, M. Dimopoulos, D. Reece, 2010, Cancer.

Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A. Beaven, Carlos M. de Castro, P. Islam, 2021, Cancer investigation.

Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B‐cell Non‐Hodgkin Lymphoma

B. Heyman, David John Adams, D. Rizzieri, 2018, Clinical lymphoma, myeloma & leukemia.

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

Elizabeth M. Hollinger, Shannon R. McCurdy, H. Deeg, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study.

A. Abernethy, G. Samsa, J. Troy, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.